抗不整脈薬の世界市場：薬剤クラス別、投与経路別、流通チャネル別、地域別、機会、予測、2018年～2032年

世界の抗不整脈薬の市場規模は、2025年～2032年の予測期間中に6.22％のCAGRで拡大し、2024年の11億5,000万米ドルから2032年には18億6,000万米ドルに成長すると予測されています。同市場の成長は、世界中で心血管疾患が増加していること、一般住民の間で心臓疾患に対する意識が高まっていること、製薬会社が抗不整脈薬の製造に注力するようになっていることに起因しています。世界保健機関（WHO）は、心血管疾患が毎年約1,790万人の死亡の原因となっていると推定しています。

肥満、高血圧、糖尿病を含む生活習慣病の負担が増加していることが、抗不整脈薬に対する需要の増加に寄与しています。しかし、このクラスの薬剤の中には、催不整脈や臓器毒性などの副作用のリスクが高いものもあり、利用が制限される可能性があります。さらに、世界の高齢化人口の拡大と心臓治療における技術の進歩が、今後数年間でこれらの薬剤の採用を促進すると予想されます。

当レポートでは、世界の抗不整脈薬市場について調査し、市場の概要とともに、薬剤クラス別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界の抗不整脈薬市場の見通し、2018年～2032年

• 市場規模分析と予測
• 市場シェア分析と予測
  • 薬剤クラス別
    • ナトリウムチャネル遮断薬
    • ベータ遮断薬
    • カリウムチャネル遮断薬
    • カルシウムチャネル遮断薬
    • その他
  • 投与経路別
    • 経口
    • 非経口
    • その他
  • 流通チャネル別
    • 病院薬局
    • 小売薬局
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
• 2024年の市場マップ分析

第6章 北米の抗不整脈薬市場の見通し、2018年～2032年

第7章 欧州の抗不整脈薬市場の見通し、2018年～2032年

第8章 アジア太平洋の抗不整脈薬市場の見通し、2018年～2032年

第9章 南米の抗不整脈薬市場の見通し、2018年～2032年

第10章 中東・アフリカの抗不整脈薬市場の見通し、2018年～2032年

第11章 需要供給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

• 市場の促進要因
• 市場の課題

第17章 市場動向と発展

第18章 規制状況

第19章 臨床試験の概要

第20章 ケーススタディ

第21章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • Pfizer Inc.
  • Novartis AG
  • Mylan N.V.
  • Baxter International
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Upsher-Smith Laboratories Inc.
  • AOP Orphan Pharmaceuticals AG
  • AstraZeneca plc
  • Weefsel Pharma Limited

第22章 戦略的提言

第23章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 3. Global Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 4. Global Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 5. Global Antiarrhythmic Drugs Market Share (%), By Region, 2018-2032F
• Figure 6. North America Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 7. North America Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 8. North America Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 9. North America Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 10. North America Antiarrhythmic Drugs Market Share (%), By Country, 2018-2032F
• Figure 11. United States Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 12. United States Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 13. United States Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 14. United States Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 15. Canada Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 16. Canada Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 17. Canada Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 18. Canada Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 19. Mexico Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 20. Mexico Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 21. Mexico Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 22. Mexico Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 23. Europe Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Europe Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 25. Europe Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 26. Europe Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 27. Europe Antiarrhythmic Drugs Market Share (%), By Country, 2018-2032F
• Figure 28. Germany Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Germany Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 30. Germany Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 31. Germany Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 32. France Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 33. France Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 34. France Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 35. France Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 36. Italy Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 37. Italy Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 38. Italy Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 39. Italy Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 40. United Kingdom Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 41. United Kingdom Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 42. United Kingdom Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 43. United Kingdom Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 44. Russia Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Russia Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 46. Russia Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 47. Russia Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 48. Netherlands Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 49. Netherlands Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 50. Netherlands Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 51. Netherlands Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 52. Spain Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 53. Spain Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 54. Spain Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 55. Spain Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 56. Turkey Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 57. Turkey Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 58. Turkey Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 59. Turkey Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 60. Poland Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 61. Poland Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 62. Poland Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 63. Poland Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 64. Asia-Pacific Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 65. Asia-Pacific Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 66. Asia-Pacific Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 67. Asia-Pacific Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 68. Asia-Pacific Antiarrhythmic Drugs Market Share (%), By Country, 2018-2032F
• Figure 69. India Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 70. India Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 71. India Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 72. India Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 73. China Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 74. China Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 75. China Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 76. China Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 77. Japan Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 78. Japan Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 79. Japan Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 80. Japan Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 81. Australia Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 82. Australia Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 83. Australia Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 84. Australia Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 85. Vietnam Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 86. Vietnam Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 87. Vietnam Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 88. Vietnam Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 89. South Korea Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 90. South Korea Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 91. South Korea Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 92. South Korea Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 93. Indonesia Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 94. Indonesia Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 95. Indonesia Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 96. Indonesia Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 97. Philippines Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 98. Philippines Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 99. Philippines Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 100. Philippines Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 101. South America Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 102. South America Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 103. South America Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 104. South America Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 105. South America Antiarrhythmic Drugs Market Share (%), By Country, 2018-2032F
• Figure 106. Brazil Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 107. Brazil Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 108. Brazil Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 109. Brazil Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 110. Argentina Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 111. Argentina Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 112. Argentina Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 113. Argentina Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 114. Middle East & Africa Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 115. Middle East & Africa Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 116. Middle East & Africa Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 117. Middle East & Africa Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 118. Middle East & Africa Antiarrhythmic Drugs Market Share (%), By Country, 2018-2032F
• Figure 119. Saudi Arabia Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 120. Saudi Arabia Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 121. Saudi Arabia Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 122. Saudi Arabia Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 123. UAE Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 124. UAE Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 125. UAE Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 126. UAE Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 127. South Africa Antiarrhythmic Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 128. South Africa Antiarrhythmic Drugs Market Share (%), By Drug Class, 2018-2032F
• Figure 129. South Africa Antiarrhythmic Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 130. South Africa Antiarrhythmic Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 131. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 132. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Global antiarrhythmic drugs market is projected to witness a CAGR of 6.22% during the forecast period 2025-2032, growing from USD 1.15 billion in 2024 to USD 1.86 billion in 2032. The market's growth can be attributed to increasing cardiovascular diseases across the globe, rising awareness about cardiac conditions among the general population, and growing focus of pharmaceutical companies on manufacture antiarrhythmic drugs. The World Health Organization (WHO) estimates that cardiovascular diseases are responsible for approximately 17.9 million deaths every year.

The increasing burden of lifestyle-related disorders, including obesity, hypertension, and diabetes, contributes to the growing demand for antiarrhythmic medications. However, some drugs in this class carry a high risk of adverse effects, including proarrhythmia and organ toxicity, which may limit their utilization. Additionally, the expansion of the global aging population and technological advancements in cardiac care are expected to boost the adoption of these drugs in the coming years.

Increasing Prevalence of Cardiovascular Diseases Boosts Market Demand

Rising cases of cardiovascular diseases are influencing the market's growth, with arrhythmias such as atrial fibrillation (AF) being one of the most common types of cardiac conditions. Atrial fibrillation is one of the most common arrhythmias that causes and contributes greatly to incidences of stroke across the globe. Expansion of the aging population and poor lifestyle choices are further anticipated to increase the incidence of AF and other arrhythmias. Thus, healthcare providers are emphasizing early screening, diagnosis, and management of arrhythmia among the patient population.

Advanced diagnostic tools such as wearable ECG monitors and AI-based platforms for rhythm detection are also creating a streamlined, faster, and precise identification of arrhythmia, aiding in initiating treatment protocols that include antiarrhythmic medications in a time-efficient manner. Thus, leading medical device manufacturers focus on developing various arrhythmia monitoring devices. For instance, in January 2025, Medtronic plc announced results from their DEFINE AFib clinical study, demonstrating that Medtronic's LINQ family of insertable cardiac monitors (ICMs), including Reveal LINQ and LINQ II, utilize AI-based algorithms to predict risk thresholds for patients with AF accurately and were able to detect AF episodes and stratify patients into high-risk categories. Such technological integration in patient care increases the accuracy of decision-making, thereby positively impacting the demand for antiarrhythmic medications.

Growth of the Aging Population Supports Market Expansion

The growth of the aging population is a major driver for the expansion of the antiarrhythmic drugs market, as the older population is at a higher risk of developing cardiovascular diseases, including arrhythmias. The World Health Organization estimates that one in six people across the globe will be 60 or older by 2030. The growing elderly population leads to greater demand for effective antiarrhythmic therapies, as these therapeutic solutions are essential for controlling abnormal heart rhythms and reducing the risk of complications such as stroke and heart failure. Additionally, the increased healthcare expenditure, improved access to medical care, and heightened awareness about cardiovascular health among the elderly are further supporting the market's growth.

Retail Pharmacies Account for Significant Share of the Market

The retail pharmacy segment accounts for a major share of the global antiarrhythmic drugs market due to convenience and established patient trust in these institutions. Antiarrhythmic drugs are often prescribed for prolonged treatment in conditions such as atrial fibrillation and ventricular tachycardia; continuous and easy access to these drugs is very important for compliance and, consequently, good management of the diseases. Retail pharmacies provide patients with easy access to fill prescriptions time-efficiently, receive consultative advice from the pharmacist, and obtain refills without the need for hospital visits, further increasing their popularity, especially among the elderly who might be facing mobility issues.

Meanwhile, online pharmacies across the globe are working on increasing the availability of same-day delivery services. In October 2024, Amazon Pharmacy, a division of Amazon.com, Inc., unveiled plans to expand its same-day medication delivery service, doubling the number of cities covered. Leveraging cutting-edge automation and an extensive logistics network, the company seeks to address key challenges in the pharmacy industry, including improving affordability and enhancing convenience for patients.

North America Holds Major Market Share

The market's dominance in the region can be attributed to advanced healthcare infrastructure, high healthcare spending, widespread availability of cardiac diagnostic tools, and the presence of leading pharmaceutical manufacturers. The high prevalence of atrial fibrillation and ventricular arrhythmias, especially among the elderly population, are further driving the utilization of antiarrhythmic drugs. According to the estimates of the Centers for Disease Control and Prevention, approximately 12.1 million people in the United States have atrial fibrillation. This growing burden underscores the critical need for effective pharmacological interventions. Moreover, a large number of clinical trials and Food and Drug Administration (FDA) approvals for cardiovascular drugs originate in the United States, ensuring early market access to novel therapeutic solutions.

As digital health technology integrates more deeply into cardiovascular care, arrhythmia management is expected to become more efficient and tailored, creating new opportunities for drug developers based in the region. The emergence of minimally invasive interventions and hybrid therapy models that combine pharmacological and non-pharmacological approaches could also reshape treatment paradigms, providing lucrative growth opportunities for the market in North America.

Impact of the U.S. Tariff on Global Antiarrhythmic Drugs Market

The recent imposition of tariffs is expected to significantly impact the market and affect the affordability and availability of generic medications. The tariffs are also expected to disrupt pharmaceutical supply chains, especially for generics that usually rely on low-cost active pharmaceutical ingredients. The introduction of tariffs on pharmaceutical imports could also result in delays in sourcing critical drugs and increased costs, resulting in a shortage of essential drugs, including cardiovascular medicines. Pharmaceutical companies may explore alternative sourcing strategies, strengthening partnerships with suppliers across various regions. Additionally, a new dialogue between the policymakers and industry stakeholders will be crucial in navigating the trade complexities associated with the tariffs and ensuring public access to essential medications.

Key Players Landscape and Outlook

The key players in the market are collaborating with leading educational institutions to support the advancement of diagnostic techniques and treatment solutions for cardiac conditions. For instance, the American College of Cardiology (ACC) and Pfizer Inc. are collaborating to provide new grant opportunities for enhancing the identification and diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) among heart failure patients, the RFP date for which was April 2, 2025. Pfizer will provide funding, while ACC will oversee the selection of an Expert Review Panel (ERP) and create a community of practice for grantees. This initiative aligns with Pfizer's broader Global Medical Grants & Partnerships (GMGP) strategy, which supports independent healthcare projects to improve patient outcomes in areas where the medical requirements of the patient population are still unmet.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Antiarrhythmic Drugs Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drug Class
    • 5.2.1.1. Sodium Channel Blockers
    • 5.2.1.2. Beta Blockers
    • 5.2.1.3. Potassium Channel Blockers
    • 5.2.1.4. Calcium Channel Blockers
    • 5.2.1.5. Others
  • 5.2.2. By Route of Administration
    • 5.2.2.1. Oral
    • 5.2.2.2. Parenteral
    • 5.2.2.3. Others
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Others
  • 5.2.4. By Region
    • 5.2.4.1. North America
    • 5.2.4.2. Europe
    • 5.2.4.3. Asia-Pacific
    • 5.2.4.4. South America
    • 5.2.4.5. Middle East and Africa
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Drug Class
  • 5.3.2. By Route of Administration
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Antiarrhythmic Drugs Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Drug Class
    • 6.2.1.1. Sodium Channel Blockers
    • 6.2.1.2. Beta Blockers
    • 6.2.1.3. Potassium Channel Blockers
    • 6.2.1.4. Calcium Channel Blockers
    • 6.2.1.5. Others
  • 6.2.2. By Route of Administration
    • 6.2.2.1. Oral
    • 6.2.2.2. Parenteral
    • 6.2.2.3. Others
  • 6.2.3. By Distribution Channel
    • 6.2.3.1. Hospital Pharmacies
    • 6.2.3.2. Retail Pharmacies
    • 6.2.3.3. Others
  • 6.2.4. By Country Share
    • 6.2.4.1. United States
    • 6.2.4.2. Canada
    • 6.2.4.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Antiarrhythmic Drugs Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
        • 6.3.1.1.1.1. Market Share Analysis & Forecast
      • 6.3.1.1.2. By Drug Class
        • 6.3.1.1.2.1. Sodium Channel Blockers
        • 6.3.1.1.2.2. Beta Blockers
        • 6.3.1.1.2.3. Potassium Channel Blockers
        • 6.3.1.1.2.4. Calcium Channel Blockers
        • 6.3.1.1.2.5. Others
      • 6.3.1.1.3. By Route of Administration
        • 6.3.1.1.3.1. Oral
        • 6.3.1.1.3.2. Parenteral
        • 6.3.1.1.3.3. Others
      • 6.3.1.1.4. By Distribution Channel
        • 6.3.1.1.4.1. Hospital Pharmacies
        • 6.3.1.1.4.2. Retail Pharmacies
        • 6.3.1.1.4.3. Others
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Antiarrhythmic Drugs Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Antiarrhythmic Drugs Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Antiarrhythmic Drugs Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Antiarrhythmic Drugs Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Landscape

19. Overview of Clinical Trials

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. Pfizer Inc.
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 21.3.2. Novartis AG
  • 21.3.3. Mylan N.V.
  • 21.3.4. Baxter International
  • 21.3.5. GlaxoSmithKline plc
  • 21.3.6. Sanofi S.A.
  • 21.3.7. Upsher-Smith Laboratories Inc.
  • 21.3.8. AOP Orphan Pharmaceuticals AG
  • 21.3.9. AstraZeneca plc
  • 21.3.10. Weefsel Pharma Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer